Dr Simon Stott
Simon is Director of Research at Cure Parkinson’s.
Simon leads on fostering promising new lines of research, promoting beneficial worldwide scientific and clinical collaborations across the community. Simon plays a leading role in the ongoing growth of Cure Parkinson’s International Linked Clinical Trials (iLCT) programme, working alongside the iLCT Committee to ensure the most promising drugs are prioritised for clinical trial in Parkinson’s.
Articles by Dr Simon Stott
Just a lysosomal enzyme…
About 5% of individuals affected by Parkinson’s carry a genetic variation in a region of their DNA called the GBA1 gene. This area of DNA provides the instructions for making an enzyme called GCase, which is known to be involved in cellular waste disposal. Recently, however, researchers have discovered that GCase […]
Year in review: 2022
At the end of each year, it is a useful process to take stock and review what we have learnt over the last 12 months. 2022 has been an extremely busy year for Parkinson’s research, with a lot of clinical trial results and new insights. As the world continues to re-open […]
Disease modification-ish
Semantics matters – particularly regarding our communication on ideas like “disease modification” for neurodegenerative conditions. There is a big difference between “disease eradication” (zero worldwide incidence), “disease correction” (the halting/reversing of progression) and “disease modification” (improving the trajectory of disease). Recently, researchers in Japan have demonstrated “disease modification” in motor neuron […]
A rising tide with liraglutide
A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of […]